In AF with recent ACS or PCI, apixaban improved 30-day outcomes vs. VKAs; aspirin effects varied vs. placebo.
Where this comes from
- Record sourced from PubMed, PMID 32926823.
- Also identified by DOI 10.7326/ACPJ202009150-029.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alexander JH, Wojdyla D, Vora AN, et al. <b>Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS.</b> Circulation. 2020;141:1618-27. 32223444.
Medical subject headings
- Acute Coronary Syndrome
- Atrial Fibrillation
- Percutaneous Coronary Intervention